Home
About Us
- Management
- Business Development
Product Pipeline
- Scientific Presentations
- Clinical Trials
Expanded Access
News & Media
Contact Us
- Reporting Concerns
BPDCN

SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels

January 1, 2015

|In Scientific Presentation, ELZONRIS

SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels. AACR 2015.

Add comment Cancel reply

Comment

Name *

Email *

Website

Prev
Next

About Us
- Management
- Business Development
Product Pipeline
- Scientific Presentations
- Clinical Trials
Contact Us
News & Media
BPDCN

© – Stemline Therapeutics, Inc. All rights reserved | Privacy & Terms of Use | CCPA Policy | Cookie Policy | Privacy Notice for Social Network Users & Netiquette |

Stemline Therapeutics is a society of the Menarini Group

Privacy Preference Center

Privacy Preferences